Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Massachusetts General Hospital · Mass General Brigham
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
474
total citations
- FWCI
- 64.67
- Percentile
- 100%
- References
- 281
Citations per year
Authors
3- AJAlissa J. CooperCorresponding
Massachusetts General Hospital
- LVLecia V. Sequist
Massachusetts General Hospital
- JJJessica J. Lin
Massachusetts General Hospital, Mass General Brigham
Topics & keywords
Topics
Keywords
- Osimertinib
- Medicine
- Acquired resistance
- Cancer research
- Lung cancer
- Anaplastic lymphoma kinase
- Tyrosine kinase
- Disease
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.